PGP and colorectal cancer: Moreover, elacridar at 0.5 μM concentration improved sunitinib efficacy in P-gp and/or BCRP overexpressing colorectal cancer cell lines (HT29, COLO320, DLD1, and CACO2) as well as patient-derived organoids [66].